EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Kuvalanka Bolts Blueprint Medicines For COO Gig at Syros

Xconomy Boston — 

Kyle Kuvalanka has been named the first chief operating officer of Cambridge, MA-based Syros Pharmaceuticals, a privately held startup developing so-called “gene control” drugs. Kuvalanka was previously the chief business officer of Blueprint Medicines (NASDAQ: BPMC), which went public and raised nearly $150 million in an IPO in April.